RECENT Healthcare RESEARCH
On November 30, 2017, Varian Medical Systems (VAR) was trading at its 52-week high of $111.40. On November 29, it ended trading at $111.20, its highest closing price for the last 52 weeks.
Medtronic (MDT) reported net adjusted profits of ~$1.5 billion for fiscal 2Q18, an ~7.0% year-over-year decline. This report included an ~3.0% negative impact resulting from Hurricane Maria.
Myriad Genetics reported fiscal 1Q18 revenues and adjusted EPS of ~$190 million and ~$0.26, respectively, surpassing the analyst estimates.
BAX stock reached its 52-week high on October 27, triggered by positive investor sentiment following its stellar quarterly performance and future outlook.
In 3Q17, Bristol-Myers Squibb (BMY) reported revenues of $5.3 billion, a ~7% increase on a year-over-year (or YoY) basis and a 2% increase on a quarter-over-quarter basis.
BD released its 4Q17 and fiscal 2017 earnings results on November 2, 2017. That day, the stock rose ~7.7%, registering a record high thanks to the company’s stellar earnings results.
In 3Q17, Pfizer (PFE) generated revenues of $13.2 billion, an increase of ~1% on a year-over-year (or YoY) basis and a 1% increase on a quarter-over-quarter basis.
In 3Q17, Nektar Therapeutics (NKTR) reported revenues of $152.9 million, a YoY rise of 320.7%. The sudden spurt is mainly due to the upfront payment of $150 million from Eli Lilly.
Eli Lilly (LLY) reported 9% YoY (year-over-year) growth in its top line to ~$5.7 billion for 3Q17.
Medtronic released its 2Q18 earnings results on November 21, 2017. The company registered sales of around $7.1 billion, representing a YoY (year-over-year) decline of around 4%.
As of November 21, 2017, Johnson & Johnson was trading at a forward PE multiple of ~17.6x as compared to the industry average of 16.2x.
Abbott registered strong 3Q17 results, surpassing estimates for both sales and earnings and reporting healthy growth across all of its business segments.
Teva (TEVA) reported 3Q17 revenues of $5.6 billion, which represents a ~1% YoY (year-over-year) rise but a 1% QoQ (quarter-over-quarter) fall.
According to Synergy, it’s estimated that ~33 million people suffer from CIC and 12 million people suffer from IBS-C in the US.
Exelixis (EXEL) reported total revenues of ~$152.5 million in 3Q17, which represented a YoY rise of ~145.2%, mainly due to rising demand for Cabometyx.
In 3Q17, Merck (MRK) reported revenue of $10.3 billion, which reflected a ~2% fall YoY (year-over-year) and ~4% growth QoQ (quarter-over-quarter).
In 3Q17, Johnson & Johnson (JNJ) reported ~$19.7 billion in sales. The company’s Medical Devices business generated ~33.5% of the total sales.
In 3Q17, Edwards Lifesciences (EW) reported adjusted sales of ~$838 million, which is an underlying growth of ~13% on a YoY basis. This performance was driven by double-digit organic growth.
Of the 21 analysts covering Endo in November 2017, six recommend a “buy” for the stock, while 14 recommend a “hold,” and one recommends a “sell.”
In 3Q17, AstraZeneca reported EPS of $0.56 on revenues of $6.2 billion compared to estimates of $0.71 for EPS on revenues of $6 billion.